Ipsen Crecimiento futuro
Future controles de criterios 1/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Ipsen de 11.6% y 4.2% por año respectivamente. Se prevé que el BPA crezca en un 13.2% al año. Se espera que la rentabilidad financiera sea de 16.2% en 3 años.
Información clave
11.6%
Tasa de crecimiento de los beneficios
13.20%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 16.0% |
| Tasa de crecimiento de los ingresos | 4.2% |
| Rentabilidad financiera futura | 16.17% |
| Cobertura de analistas | Good |
| Última actualización | 18 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • May 17
IPN: Future Portfolio Execution And Core Pipeline Will Shape Re Rated Earnings Potential
Analysts have raised Ipsen's price target by €13 to €183, citing updated assumptions around the discount rate, revenue growth, profit margins and future P/E that align with recent upward revisions from major banks. Analyst Commentary Recent research updates point to a more constructive stance on Ipsen, with several bullish analysts revisiting their models and price targets.Actualización de narrativa • Apr 24
IPN: Future Portfolio Execution Will Drive Re Rated Earnings Power Potential
Narrative Update on Ipsen The analyst fair value estimate for Ipsen has been revised from €155 to €183. This reflects analysts' updated assumptions on higher revenue growth, a different discount rate, a higher future P/E and recent price target increases and rating changes across several banks.
Actualización de narrativa • Apr 10
IPN: Oncology Pipeline Progress And Safety Setbacks Will Shape Balanced Future Outlook
Analysts have adjusted the Ipsen price target to €151.94, with recent research pointing to updated revenue growth and profit margin assumptions, as well as fresh Street targets around €160 and €170 as key drivers of the new view. Analyst Commentary Bullish Takeaways Bullish analysts are pointing to higher price targets around €160 and €170, which reflects confidence in Ipsen’s ability to execute on its current pipeline and financial framework despite recent product-specific issues.Actualización de narrativa • Mar 27
IPN: Early Oncology Pipeline And Safety Setbacks Will Shape Future Upside
The analyst fair value estimate for Ipsen has shifted from €143 to about €152, as analysts factor in updated price targets around €160 to €170 and recent rating changes that reflect both the impact of the tazemetostat withdrawal and a focus on the broader pipeline and earnings profile. Analyst Commentary Recent research shows a split view on Ipsen, with some bullish analysts lifting price targets toward €160 to €170, while more cautious voices highlight pipeline depth and valuation risks after the tazemetostat withdrawal.
Actualización de narrativa • Mar 13
IPN: Oncology Setbacks And Limited Late Stage Pipeline Will Constrain Future Upside
The analyst fair value estimate for Ipsen has shifted from €105 to €115, with analysts pointing to recent price target revisions, mixed views on the company’s pipeline depth, and updated assumptions on margins and future P/E levels as key drivers of the change. Analyst Commentary Recent Street research around Ipsen has focused on shifting views of the company’s pipeline and valuation, with mixed reactions to the withdrawal of tazemetostat and differing opinions on the depth of late stage assets.Actualización de narrativa • Feb 27
IPN: Limited Late Stage Pipeline Will Constrain Future Upside Potential
The analyst fair value estimate for Ipsen has moved from €134.80 to €143.00, reflecting updated assumptions on revenue growth, margins, and future P/E, following recent price target changes from banks that now range from about €125 to €170. Analyst Commentary Recent research on Ipsen reflects a mix of optimism and caution, with target prices clustering between about €125 and €170 and ratings spread across Buy, Neutral, and Equal Weight.Actualización de narrativa • Feb 12
IPN: Competitive Pressures And Thin Pipeline Will Shape A Balanced Outlook
Analysts have increased their fair value estimate for Ipsen to about €135 per share from roughly €133, reflecting updated price targets that incorporate a mix of cautious views on the late stage pipeline and concerns around competitive pressures, alongside modest target increases from others. Analyst Commentary Recent research shows a split view on Ipsen, with some analysts trimming expectations and others nudging targets higher.Actualización de narrativa • Jan 29
IPN: Mixed Ratings And Limited Late Stage Assets Will Shape A Balanced Outlook
Narrative Update The updated analyst price target for Ipsen moves modestly higher to about €133 from about €131. Analysts point to slightly stronger revenue growth and margin assumptions, while also flagging ongoing concerns about limited late stage assets and competitive pressure on Somatuline, as reflected in recent mixed rating and target changes from UBS, Barclays, and BNP Paribas Exane.Actualización de narrativa • Jan 15
IPN: Mixed Ratings And Pipeline Setbacks Will Shape A Cautious Yet Balanced Outlook
Our updated fair value estimate for Ipsen edges up from €130.07 to €130.79. This reflects a blend of mixed Street signals, where some analysts point to valuation constraints and pipeline depth, while others lift price targets in line with current expectations.Actualización de narrativa • Dec 21
IPN: Guidance Upgrade And Competitive Pressures Will Shape A Cautious Yet Balanced Outlook
Analysts have reduced their price target on Ipsen from EUR 130.07 to EUR 105.00, citing increased competitive pressure on Somatuline as a key driver of the downgrade. Analyst Commentary Analysts note that the reduced price target reflects a reassessment of Ipsen's risk and reward profile in light of mounting competition for Somatuline, which is expected to weigh on both top line momentum and margin resilience.Actualización de narrativa • Dec 07
IPN: Guidance Upgrade And Competition Concerns Will Shape Balanced Future Outlook
Analysts have trimmed their price target on Ipsen by approximately EUR 1 to around EUR 130, reflecting slightly lower long term growth and margin expectations amid rising competitive pressure on key drug Somatuline. Analyst Commentary Analyst sentiment around Ipsen has turned more cautious, with recent revisions reflecting heightened concern about the sustainability of growth in key endocrine oncology franchises and the implications for valuation.Actualización de narrativa • Nov 22
IPN: Guidance Upgrade And New Approvals Will Support Balanced Outlook
Narrative Update on Ipsen Analysts have maintained their fair value estimate for Ipsen at €130.79 per share. They cite minimal changes in key assumptions and only slight fluctuations in projected growth and profitability.Actualización de narrativa • Nov 07
IPN: Future Opportunities And Risks Are Balanced Following Guidance Upgrade
Narrative Update on Ipsen: Analyst Price Target Adjustment Analysts have raised their price target for Ipsen to €130.79, up from €129.93. This change reflects slight improvements in expected revenue growth and profit margin, despite a marginally higher discount rate.Artículo de análisis • Oct 28
Ipsen (EPA:IPN) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Actualización de narrativa • Oct 24
Global Approvals And Guidance Will Drive Expanded Patient Access Worldwide
Narrative Update on Ipsen: Analyst Price Target Adjustment Analysts have slightly increased their price target for Ipsen from $128.43 to $129.93. This adjustment is attributed to minor shifts in revenue growth forecasts and updated profit margin estimates.Actualización de narrativa • Sep 25
Pipeline Catalysts And Approvals Will Expand Global Access
Driven by a modest uptick in consensus revenue growth forecasts and a slight increase in the projected future P/E, Ipsen’s analyst price target has inched up from €127.00 to €128.43. What's in the News Ipsen received Japanese regulatory approval for Bylvay (odevixibat) for the treatment of pruritus associated with progressive familial intrahepatic cholestasis (PFIC), with commercialization managed by Ipsen in Japan.Artículo de análisis • Sep 07
Are Investors Undervaluing Ipsen S.A. (EPA:IPN) By 41%?
Key Insights Ipsen's estimated fair value is €205 based on 2 Stage Free Cash Flow to Equity Current share price of €120...Artículo de análisis • Jul 13
Investors Interested In Ipsen S.A.'s (EPA:IPN) Earnings
Ipsen S.A.'s ( EPA:IPN ) price-to-earnings (or "P/E") ratio of 24.5x might make it look like a strong sell right now...
Nueva narrativa • Feb 23
Cabometyx And Tovorafenib Approvals May Strengthen Oncology Portfolio In 2025
Expansion of Onivyde and new product approvals could significantly increase revenue and strengthen market positions in key medical segments.Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 4,669 | 932 | 1,092 | 1,209 | 8 |
| 12/31/2027 | 4,387 | 886 | 1,044 | 1,117 | 12 |
| 12/31/2026 | 4,238 | 895 | 1,026 | 1,371 | 11 |
| 12/31/2025 | 3,929 | 444 | 810 | 1,138 | N/A |
| 9/30/2025 | 3,845 | 446 | 703 | 1,057 | N/A |
| 6/30/2025 | 3,760 | 448 | 595 | 976 | N/A |
| 3/31/2025 | 3,667 | 402 | 364 | 946 | N/A |
| 12/31/2024 | 3,575 | 356 | 133 | 916 | N/A |
| 6/30/2024 | 3,435 | 664 | 212 | 903 | N/A |
| 3/31/2024 | 3,371 | 641 | 445 | 884 | N/A |
| 12/31/2023 | 3,306 | 617 | 677 | 866 | N/A |
| 6/30/2023 | 3,282 | 406 | 764 | 972 | N/A |
| 3/31/2023 | 3,219 | 500 | 741 | 971 | N/A |
| 12/31/2022 | 3,156 | 593 | 719 | 971 | N/A |
| 9/30/2022 | 3,053 | 656 | 615 | 972 | N/A |
| 6/30/2022 | 2,950 | 719 | 512 | 973 | N/A |
| 3/31/2022 | 2,849 | 675 | 494 | 933 | N/A |
| 12/31/2021 | 2,749 | 631 | 475 | 893 | N/A |
| 9/30/2021 | 2,712 | 626 | 570 | 860 | N/A |
| 6/30/2021 | 2,676 | 622 | 665 | 827 | N/A |
| 3/31/2021 | 2,681 | 585 | 649 | 799 | N/A |
| 12/31/2020 | 2,686 | 548 | 632 | 771 | N/A |
| 9/30/2020 | 2,697 | 249 | 564 | 750 | N/A |
| 6/30/2020 | 2,707 | -50 | 496 | 729 | N/A |
| 3/31/2020 | 2,700 | -53 | 421 | 678 | N/A |
| 12/31/2019 | 2,693 | -55 | 347 | 628 | N/A |
| 9/30/2019 | 2,605 | 176 | N/A | 591 | N/A |
| 6/30/2019 | 2,516 | 406 | N/A | 555 | N/A |
| 3/31/2019 | 2,432 | 397 | N/A | 563 | N/A |
| 12/31/2018 | 2,348 | 388 | N/A | 571 | N/A |
| 9/30/2018 | 2,258 | 365 | N/A | N/A | N/A |
| 6/30/2018 | 2,167 | 343 | N/A | 502 | N/A |
| 3/31/2018 | 2,090 | 307 | N/A | 463 | N/A |
| 12/31/2017 | 2,012 | 270 | N/A | 423 | N/A |
| 9/30/2017 | 1,923 | 243 | N/A | N/A | N/A |
| 6/30/2017 | 1,834 | 217 | N/A | 316 | N/A |
| 3/31/2017 | 1,753 | 221 | N/A | 317 | N/A |
| 12/31/2016 | 1,671 | 226 | N/A | 318 | N/A |
| 9/30/2016 | 1,623 | 229 | N/A | N/A | N/A |
| 6/30/2016 | 1,575 | 233 | N/A | 318 | N/A |
| 3/31/2016 | 1,548 | 211 | N/A | 271 | N/A |
| 12/31/2015 | 1,520 | 189 | N/A | 224 | N/A |
| 9/30/2015 | 1,468 | 165 | N/A | 225 | N/A |
| 6/30/2015 | 1,416 | 140 | N/A | 227 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (11.6% al año) de IPN es superior a la tasa de ahorro (2.5%).
Beneficios vs. Mercado: Se prevé que los beneficios (11.6% al año) de IPN crezcan menos que el mercado French (12.4% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de IPN crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (4.2% al año) de IPN crezcan más despacio que el mercado de French (5.6% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 4.2% al año) de IPN crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de IPN sea baja dentro de 3 años (16.2%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/21 11:24 |
| Precio de las acciones al final del día | 2026/05/21 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Ipsen S.A. está cubierta por 25 analistas. 12 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Charles Pitman | Barclays |
| Yihan Li | Barclays |
| Charles Pitman | Barclays |